News
SpringWorks Therapeutics Shares Rise Following WSJ Report of Merck KGaA Deal
Shares of SpringWorks Therapeutics climbed after The Wall Street Journal reported that Germany's Merck KGaA is nearing a $3.5 billion deal for the U.S. biopharmaceutical company. SpringWorks stock rose 8.7%, to $44.80, in afternoon trading Thursday. Shares are up 2.3% in the past year.
So far, SpringWorks – which was spun out of Pfizer in 2017 and has recently received FDA approval for a second therapy for a ...
Merck on Thursday said its first-quarter adjusted profit rose 7% as lower costs helped offset a 2% decline in sales, ...
MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology ...
Germany’s Merck KGaA (MKGAY), which had confirmed in February it was in advanced talks to buy SpringWorks Therapeutics (SWTX), is nearing a roughly $3.5B deal for the U.S. biopharmaceutical ...
This integration builds trust in AI systems regarding data authenticity and origin,” said Thomas Endress, Head of M-Trust™, Merck KGaA, Darmstadt, Germany. “Our collaboration with Zebra ...
Germany's Merck KGaA said on Thursday it is in late-stage talks to acquire U.S.-based SpringWorks Therapeutics for about $3.5 ...
Newsable Asianet News on MSN1d
SpringWorks Therapeutics Retail Chatter Spikes As Germany’s Merck Confirms Late-Stage Talks For $3.5B BuyoutShares of SpringWorks Therapeutics Inc. ended over 9% higher on Thursday following a report that the company is inching ...
Merck will partner with Chinese biotech Abbisko ... expanding its commercialization rights for the drug beyond Asia. The German pharmaceutical company said Friday that it would pay Abbisko an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback